Your Health, We Care
Release date: 2026-01-28 17:43:34 Recommended: 11
Administration of rivoceranib is continued until disease progression, occurrence of intolerable toxicity, failure to achieve morphologic leukemia-free state after 4 cycles of treatment, or the patient undergoes hematopoietic stem cell transplantation (HSCT).
The efficacy of this drug was evaluated in an open-label, multicenter, single-arm cohort trial, which enrolled 104 adult and pediatric patients (aged ≥30 days) with relapsed or refractory (R/R) acute leukemia harboring KMT2A gene translocation, excluding patients with 11q23 partial tandem duplication mutations.
If differentiation syndrome is suspected, systemic glucocorticoids should be administered immediately, and hemodynamic monitoring should be initiated. Monitoring should be continued until symptom resolution and maintained for at least 3 days.
If severe signs and/or symptoms persist for more than 48 hours after the administration of systemic glucocorticoids, or life-threatening symptoms occur (e.g., pulmonary symptoms requiring ventilator support), Revuforj should be discontinued immediately. Revuforj may be resumed at the original dose when signs and symptoms improve to Grade 1* or lower.
For patients with elevated or rapidly rising white blood cell counts, hydroxyurea therapy should be initiated immediately; leukapheresis may be added if clinically indicated.
Hydroxyurea may only be tapered gradually after the symptoms of leukocytosis improve or resolve.
Hold Revuforj administration.
Test electrolyte levels and correct hypokalemia and hypomagnesemia.
Revuforj may be restarted at the original dose after the corrected QT interval returns to ≤480 milliseconds.
